Test Catalog

Test Id : CDAU

Drug Abuse Survey with Confirmation, Random, Urine

Useful For
Suggests clinical disorders or settings where the test may be helpful

Detecting drug abuse involving amphetamines, barbiturates, benzodiazepines, cocaine, ethanol, marijuana, opiates, and phencyclidine

 

This test is intended to be used in a setting where the test results can be used definitively to make a diagnosis.

Reflex Tests
Lists tests that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial tests.

Test Id Reporting Name Available Separately Always Performed
AMPHU Amphetamines Confirmation, U Yes No
OPATU Opiate Confirmation, U Yes No
BARBU Barbiturates Confirmation, U Yes No
COKEU Cocaine and metabolite Conf, U Yes No
ETOH Ethanol, U No No
PCPU Phencyclidine Confirmation, U Yes No
THCU Carboxy-THC Confirmation, U Yes No
BNZU Benzodiazepines Confirmation, U Yes No

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Testing begins with screening assays. If alcohol (ethanol) screen is positive, then the gas chromatography-flame ionization detector confirmation with quantification will be performed at an additional charge. If barbiturates, benzodiazepines, cocaine and metabolites, phencyclidine, or tetrahydrocannabinol metabolite screen is positive, then the gas chromatography-mass spectrometry (GC-MS) confirmation with quantification will be performed at an additional charge. Amphetamines and opiates that screen positive will be quantified with liquid chromatography-tandem mass spectrometry (LC-MS/MS) at an additional charge.

Method Name
A short description of the method used to perform the test

CDAU: Alcohol Screened by an Enzymatic Assay/All Others Screened by Immunoassay

ETOH: Gas Chromatography-Mass Spectrophotometry (GC-MS)

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

Confirmed Drug Abuse Panel, U

Aliases
Lists additional common names for a test, as an aid in searching

7-Amino Flunitrazepam (Metabolite of Flunitrazepam) (Rohypnol)

Alcohol

Alprazolam (Xanax)

Amobarbital (Amytal)

Amphetamines

Amytal (Amobarbital)

Angel Dust (Phencyclidine)

Ativan (Lorazepam)

Barbita (Phenobarbital)

Barbiturates

Benzodiazepines

Benzoylecgonine (Cocaine Metabolite)

Butabarbital (Butisol)

Butalbital (Fiorinal)

Butisol (Butabarbital)

Cannabinoids (Tetrahydrocannabinol)

Chlordiazepoxide (Librium)

Clorazepate (Tranxene)

Cocaine

Codeine

Coke (Cocaine)

Crack (Cocaine)

Dalmane (Flurazepam)

Date Rape Drug (Rohypnol [Flunitrazepam])

Desalkyl Flurazepam (Metabolite)

Desoxyn (Methamphetamines)

Diazepam (Valium)

Dilaudid (Hydromorphone)

Drugs of Abuse

Ecstasy

Ethanol

Ethyl Alcohol

ETOH (Ethanol)

Fiorinal (Butalbital)

Flunitrazepam (Rohypnol)

Flurazepam (Dalmane)

Halicon (Triazolam)

Heroin

Hycodan (Hydrocodone)

Hydrocodone (Hycodan, Vicodin)

Hydromorphone (Dilaudid, Vicodin)

Hydroxy-Ethyl Flurazepam (Metabolite of Flurazepam) (Dalmane)

Killer Weed (Phencyclidine)

Librium (Chlordiazepoxide)

Lorazepam (Ativan)

Lortab (Hydromorphone)

Luminal (Phenobarbital)

Marijuana (Tetrahydrocannabinol)

MDA (Methylenedioxyamphetamine) Metabolite for Methylenedioxyethylamphetamine (MDEA) and Methylenedioxymethamphetamine (MDMA)

MDMA (Methylenedioxymethamphetamine)

Mebaral (Mephobarbital)

Mephobarbital (Mebaral)

Methamphetamines (Desoxyn)

Methylenedioxyamphetamine (MDA) Metabolite for Methylenedioxyethylamphetamine (MDEA) and Methylenedioxymethamphetamine (MDMA)

Methylenedioxymethamphetamine (MDMA)

Morphine

Nembutal (Pentobarbital)

Nordiazepam (Tranxene)

Opiates

Oxazepam (Serax)

Oxycodone (Oxycontin, Percodan)

Oxycontin (Oxycodone)

PCP (Phencyclidine)

Pentobarbital (Nembutal)

Pentothal (Thiopental)

Percodan (Oxycodone)

Phencyclidine (PCP)

Phenobarbital

Restoril (Temazepam)

Rocket Fuel (Phencyclidine)

Rohypnol (Flunitrazepam)

Secobarbital (Seconal)

Seconal (Secobarbital)

Serax (Oxazepam)

Solfoton (Phenobarbital)

Speed (Amphetamines)

TCP (Phencyclidine)

Temazepam (Restoril)

Tetrahydrocannabinol (THC)

THC (Tetrahydrocannabinol)

Thiopental (Pentothal)

Toxicology Screen, Drugs

Tranxene (Clorazepate)

Triazolam (Halcion)

Tuinal (Amobarbital and Secobarbital)

Valium (Diazepam)

Vicodin (Hydrocodone)

Xanax (Alprazolam)

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Testing begins with screening assays. If alcohol (ethanol) screen is positive, then the gas chromatography-flame ionization detector confirmation with quantification will be performed at an additional charge. If barbiturates, benzodiazepines, cocaine and metabolites, phencyclidine, or tetrahydrocannabinol metabolite screen is positive, then the gas chromatography-mass spectrometry (GC-MS) confirmation with quantification will be performed at an additional charge. Amphetamines and opiates that screen positive will be quantified with liquid chromatography-tandem mass spectrometry (LC-MS/MS) at an additional charge.

Specimen Type
Describes the specimen type validated for testing

Urine

Ordering Guidance

For situations where chain of custody is required, a Chain of Custody Kit (T282) is available. For chain-of-custody information, see CDAUX / Drug Abuse Panel with Confirmation, Chain of Custody, Urine.

Additional Testing Requirements

If urine creatinine is required or adulteration of the sample is suspected, the following test should be requested, ADULT / Adulterants Survey, Urine.

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Supplies: Urine Container, 60 mL (T313)

Collection Container/Tube: Plastic urine container

Submission Container/Tube: Plastic, 60-mL urine container (T313)

Specimen Volume: 30 mL

Collection Instructions:

1. Collect a random urine specimen.

2. Submit 30 mL in 1 plastic container.

3. No preservative.

Additional Information:

1. No specimen substitutions.

2. Additional drug panels and specific requests are available. Call 800-533-1710 or 507-266-5700.

3. Submitting less than 30 mL will compromise our ability to perform all necessary testing.

Forms

If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory

15 mL

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Urine Refrigerated (preferred) 7 days
Frozen 14 days

Useful For
Suggests clinical disorders or settings where the test may be helpful

Detecting drug abuse involving amphetamines, barbiturates, benzodiazepines, cocaine, ethanol, marijuana, opiates, and phencyclidine

 

This test is intended to be used in a setting where the test results can be used definitively to make a diagnosis.

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Testing begins with screening assays. If alcohol (ethanol) screen is positive, then the gas chromatography-flame ionization detector confirmation with quantification will be performed at an additional charge. If barbiturates, benzodiazepines, cocaine and metabolites, phencyclidine, or tetrahydrocannabinol metabolite screen is positive, then the gas chromatography-mass spectrometry (GC-MS) confirmation with quantification will be performed at an additional charge. Amphetamines and opiates that screen positive will be quantified with liquid chromatography-tandem mass spectrometry (LC-MS/MS) at an additional charge.

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

This assay was designed to screen by immunoassay and confirm by gas chromatography-mass spectrometry (GC-MS), gas chromatography-flame ionization detection (GC-FID), or liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the following drugs:

-Amphetamines

-Barbiturates

-Benzodiazepines

-Cocaine

-Ethanol

-Opiates

-Phencyclidine

-Tetrahydrocannabinol

 

This assay represents the coupling of an immunoassay screen with an automatic confirmation of all positive results by the definitive assay available and described in each individual reflex test ID (eg, AMPHU / Amphetamines Confirmation, Urine). All positive screening results are confirmed by GC-MS, GC-FID, or LC-MS/MS and quantitated before a positive result is reported.

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Negative

Screening cutoff concentrations

Amphetamines: 500 ng/mL

Barbiturates: 200 ng/mL

Benzodiazepines: 100 ng/mL

Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL

Ethanol: 10 mg/dL

Opiates: 300 ng/mL

Phencyclidine: 25 ng/mL

Tetrahydrocannabinol carboxylic acid: 50 ng/mL

This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.

Interpretation
Provides information to assist in interpretation of the test results

A positive result indicates that the patient has used the drugs detected in the recent past. See individual tests (eg, AMPHU / Amphetamines Confirmation, Urine) for more information.

 

For information about drug testing, including estimated detection times, see Drugs of Abuse Testing at https://www.mayocliniclabs.com/test-info/drug-book/index.html..

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Not intended for use in employment-related testing.

 

The test does not screen for drug classes other than those listed above. More comprehensive screening is available using the serum or urine drug screens (DSS / Drug Screen, Prescription/OTC, Serum or PDSU / Drug Screen, Prescription/OTC, Urine).

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Physician's Desk Reference (PDR). 60th edition. Montvale, NJ, Medical Economics Company, 2006

2. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th edition. Edited by LL Bruntman. New York, McGraw-Hill Book Company, 2006

3. Langman LJ, Bechtel L, Holstege CP: Chapter 35. In Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Edited by CA Burtis, ER Ashwood, DE Bruns. WB Saunders Company, 2011, pp 1109-1188

Method Description
Describes how the test is performed and provides a method-specific reference

The amphetamines, barbiturates, benzodiazepines, cocaine, opiates, phencyclidine, and tetrahydrocannabinol metabolite assays are based on the kinetic interaction of microparticles in a solution (KIMS) as measured by changes in light transmission. In the absence of sample drug, soluble drug conjugates bind to antibody-bound microparticles, causing the formation of particle aggregates. As the aggregation reaction proceeds in the absence of sample drug, the absorbance increases. When a urine sample contains the drug in question, this drug competes with the drug derivative conjugate for microparticle-bound antibody. Antibody bound to sample drug is no longer available to promote particle aggregation, and subsequent particle lattice formation is inhibited. The presence of sample drug diminishes the increasing absorbance in proportion to the concentration of drug in the sample. Sample drug content is determined relative to the value obtained for a known cutoff concentration of drug.

 

ADH

 

Ethyl alcohol + NAD+ -----------------> acetaldehyde + NADH + H+

 

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Monday through Saturday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

Same day/1 to 2 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

2 weeks

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

80307

LOINC® Information

Test Id Test Order Name Order LOINC Value
CDAU Confirmed Drug Abuse Panel, U 87428-9
Result Id Test Result Name Result LOINC Value
Result LOINC Value Tooltip
30909 Alcohol 34180-0
2573 Amphetamines 43983-6
2574 Barbiturates 70155-7
2575 Benzodiazepines 16195-0
21652 Cocaine 19359-9
2577 Opiates 18390-5
2578 Phencyclidine 18392-1
2664 Tetrahydrocannabinol 19415-9
20672 Chain of Custody 77202-0

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports